Therefore, with its potent activity and lack of apparent toxicity, ASR490 provides the necessary selectivity and therapeutic window for cancer therapeutics targeting the Notch1 pathway and selectively inhibiting BCSC populations within tumors. Here, NOTCH1 is linked to cancer.